Reversal of tumor-induced immunosuppression: A new approach to cancer therapy

Journal of Immunotherapy

Volumn 20, Issue 3, 1997, Pages 165-177

  Wojtowicz Praga, Slawomir ^a  

^a Theradex   (United States)

Author keywords

Cancer; Cytokines; IL 10; Immunosuppression; PGE2; Prostaglandins; TGF

Indexed keywords

INTERLEUKIN 10; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; CANCER; CANCER IMMUNOTHERAPY; DISEASE COURSE; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; REVIEW; THROMBOCYTE; TUMOR VASCULARIZATION;

ANIMALS; CYTOKINES; DINOPROSTONE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERLEUKIN-10; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031435653     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199705000-00001     Document Type: Article

References (146)

1. Bast RC Jr, Morton DL. Principles of biotherapeutics. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. Philadelphia: 1993:905-13.
2. Dutcher JP, Creekmore S, Weiss GR, et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989;7:477.
3. Fisher RI, Coltman CA, Doroshow JH, et al. Metastatic renal cell cancer treated with IL-2 and lymphokine-activated killer cells-a phase II clinical trial. Ann Intern Med 1988; 108:518.
4. Rosenberg SA, Lotze MT, Yang JG, et al. Experience with the use of high dose IL-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474.
5. Khokha R, Waterhouse P. The role of tissue inhibitor of metal-loproteinase-1 in specific aspects of cancer progression and re-production. J Neurooncol 1993;18:123-7.
6. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
7. Bast RC Jr, Boyer CM. Tumor immunology. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. Philadelphia; 1993:171-97.
8. Takahashi K, Ono K, Hirabayashi Y, Taniguchi M. Escape mechanisms of melanoma from immune system by soluble melanoma antigen. J Immunol 1988; 140:3244.
9. Chakraborty NG, Twardzik DR, Sivanandham MT, Ergin MT, Hellstrom KE, Mukherji B. Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J Immunol 1990; 145:2359.
10. Karp JE, Groopman JE, Broder S. Cancer in AIDS. In: DeVita VT, Heilman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: 1993:59:2093.
11. Penn I. Principles of tumor immunity: immunocompetence and cancer. In: DeVita VT, Rosenberg SA, eds. Biologic therapy of cancer: principles and practice. Philadelphia: 1995:6:103-18.
12. Filipovich AH, Mathur A, Kamat D, Kersey JH, Shapiro RS. Lymphoproliferative disorders and other tumors complicating im-munodeficiencies. Immunodeficiency 1994;5(2):91-112.
13. Cote TR, Manns A, Hardy CR, et al. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. J Natl Cancer Inst 1996;88(10):675-9.
14. Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995;103(6):748-55.
15. Benalia H, Mouquet C, Luciani J, et al. Incidence of cutaneous tumors in kidney transplant patients: a 20-year follow up. Transplant Proc 1995;27(2): 1769.
16. Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am 1993;7(2):431-45.
17. Vermeer BJ, Hurks M. The clinical relevance of immunosuppression by UV irradiation. J Photochem Photobiol B 1994;24(3): 149-54.
18. Toth A, Alfoldy F, Jaray J, Hidvegi M, Pemer F. Malignant tumors after renal transplantation. Acta Chir Hung 1992-93; 33(3):211-6.
19. Atree SV, Crilley PA, Conroy JR, Micaily B, Brodsky JT. Cancer of the esophagus following allogeneic bone marrow transplantation for acute leukemia. Am J Clin Oncol 1995; 18(4):343-47.
20. Ryffel B, Mihatsch MJ, Fisher GL. Immunosuppression and cancer: the cyclosporin case. Drug Chem Toxicol 1992; 15(2): 95-115.
21. Kruger-Krasagakes S, Krasagakis K, Garbe C, Diamantstein T. Production of cytokines by human melanoma cells and melanocytes. Recent Results Cancer Res 1995;139:155-68.
22. Blanckaert VD, Schelling ME, Elstad CA, Meadows GG. Differential growth factor production, secretion and response by high and low metastatic variants of B16BL6 melanoma. Cancer Res 1993;53:4075-81.
23. Bomstein Y, Ophir R, Harshemes H, Ben-Efraim S. Release of immunosuppressive factor(s) by MOPC-315 murine plasmacytoma cells: a possible mechanism of defense. Anticancer Res 1993;13(6A):2125-9.
24. Hao W, McDonald TL, Brunson KW, Joshi SS. Enhanced immunosuppressive activity associated with metastatic lymphoma cells. Cancer Res 1993;53(8): 1921-8.
25. Pummer K, Purstner P, Auner HL, et al. Serum immunosuppressive acid protein predicts lymph node metastases in patients with renal cell carcinoma. Br J Urol 1994;73(6):612-4.
26. Oka M, Mitsunaga H, Hazama S, Yoshino S, Suzuki T. Natural killer activity and serum immunosuppressive acidic protein levels in esophageal and gastric cancers. Surg Today 1993;23(8): 669-74.
27. Lejeune P, Lagadec P, Onier N, Pinard D, Ohshima H, Jeannin JF. Nitric oxide involvement in tumor-induced immunosuppression. J Immunol 1994;152(10):5077-83.
28. Yamashita T, Nakane A, Watanabe T, Miyoshi I, Kasai N. Evidence that alpha-fetoprotein suppresses the immunological function in transgenic mice. Biochem Biophys Res Commun 1994; 201(3): 1154-9.
29. Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC Jr. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer 1992;70(8):2137-42.
30. Grayson G, Ladisch S. Immunosuppression by human ganglio sides. II. Carbohydrate structure and inhibition of human NK activity. Cell Immunol 1992;139(1):18-29.
31. Yagita M, Seppo A, Renkonen O, Saksela E. Deacetylase activity of human tumor cells producing immunosuppressive aminosugars: its possible role in resistance to cell-mediated cytotoxicity. Cancer RES 1993;53(23):5600-4.
32. Sakata T, Iwagami S, Tsuruta Y, Suzuki S, Suzuki R. Study of natural lipocortin I: a potent mediator for macrophage-mediated immunosuppression in tumor-bearing mice. J Immunol 1993; 151(9):4964-72.
33. Saiki I, Murata J, Makabe T, et al. Inhibition of lung metastasis by synthetic and recombinant fragments of human fibronectin with functional domains. Jpn J Cancer Res 1990;81(10):1003-11.
34. Akiyama SK, Olden K, Yamada KM. Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 1995; 14(3): 173-89.
35. Rifkin DB, Kojima S, Abe M, Harpel JG. TGF-beta: structure, function, and formation. Thromb Haemost 1993;70(1):177-9.
36. Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994;8(2):133-46.
37. Guron C, Sudarshan C, Raghow R. Molecular organization of the gene encoding murine transforming growth factor beta 1. Gene 1995; 165(2):325-6.
38. Woodall CJ, McLaren LJ, Watt NJ. Sequence and chromosomal localization of the gene encoding ovine latent transforming growth factor-beta 1. Gene 1994; 150(2):371-3.
39. Kim SJ, Romeo D, Yoo YD, Park K. Transforming growth factor beta: expression in normal and pathological conditions. Horm Res 1994; 42 (1-2): 5-8.
40. Miyazono K, Ichijo H, Heldin CH. Transforming growth factor beta: latent forms, binding proteins and receptors. Growth Factors 1993;8(i): 11-22.
41. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF. Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 1995; 131(2): 539-549.
42. Locci P, Marinucci L, Lilli C, Martinese D, Becchetti E. Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res 1995;281(2):317-24.
43. Bikfalvi A. Significance of angiogenesis in tumor progression and metastasis. Eur J Cancer 1995;31 A(7-8): 1101-4.
44. Flaumenhaft R, Kojima S, Abe M, Rifkin DB. Activation of latent transforming growth factor beta. Adv Pharmacol 1993;24:51-76.
45. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 1994;269(43):26775-82.
46. Horimoto M, Kato J, Takimoto R, Terui T, Mogi Y, Niitsu Y. Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line. Br J Cancer 1995;72(3):676-82.
47. Sasaki A, Naganuma H, Satoh E, et al. Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells. Neurol Med Chir 1995;35(7):423-30.
48. Lin HY, Moustakas A. TGF-beta receptors: structure and function. Cell Mol Biol 1994;40(3):337-49.
49. Okadome T, Yamashita H, Franzen P, Moren A, Heldin CH, Miyazono K. Distinct roles of the intracellular domains of transforming growth factor-beta type I and type II receptors in signal transduction. J Biol Chem 1994;269(49):30753-6.
50. Shull MM, Doetschman T. Transforming growth factor-beta 1 in reproduction and development. Mol Reprod Dev 1994;39(2):239-416.
51. Kulkarni AB, Karlsson S. Transforming growth factor-beta 1 knockout mice: a mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol 1993; 143(1):3-9.
52. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Spom MB, Roberts AB. Maternal rescue of transforming growth factor-β1 null mice. Science 1994;264:1936-8.
53. Wall NA, Hogan BL. TGF-beta related genes in development. Curr Opin Genet Dev 1994;4(4):517-22.
54. Roberts AB, Spom MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993;8(1):l-9.
55. Norgaard P, Hougaard S, Poulsen HS, Spang-Thomsen M. Transforming growth factor beta and cancer. Cancer Treat Rev 1995;21(4):367-403.
56. Glick AB, Lee MM, Darwiche N, Kulkami AB, Karlsson S, Yuspa SH. Targeted deletion of the TGF-beta 1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 1994; 8(20):2429-40.
57. Bursch W, Oberhammer F, Jirtle RL, et al. Transforming growth factor-beta 1 as a signal for induction of cell death by apoptosis. BrJ Cancer 1993;67(3):531-6.
58. Satterwhite DJ, Moses HL. Mechanisms of transforming growth factor-beta 1-induced cell cycle arrest. Invasion Metastasis 1994-95; 14 (1-6):309-18.
59. Polyak K, Kato JY, Solomon MJ, et al. p27Kipl, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8(1):9-22.
60. Feng XH, Filvaroff EH, Derynck R. Transforming growth factor beta (TGF-beta)-induced down-regulation of cyclin A expression requires a functional TGF-beta receptor complex: characterization of chimeric and truncated type I and type II receptors. J Biol Chem 1995;270(41):24237-45.
61. Krasagakis K, Garbe C, Schrier PI, Orfanos CE. Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res 1994; 14(6B):2565-71.
62. Yamada N, Kato M, Yamashita H, et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 1995;62(4):386-92.
63. Satterwhite DJ, Moses HL. Mechanisms of transforming growth factor-beta 1-induced cell cycle arrest. Invasion Metastasis 1994-95; 14(1-6):309-18.
64. Huang F, Hsu S, Yan Z, Winawer S, Friedman E. The capacity for growth stimulation by TGF beta 1 seen only in advanced colon cancers cannot be ascribed to mutations in APC, DCC, p53 or ras. Oncogene 1994;9(12):3701-6.
65. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Antitransforming growth factor beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. J Clin Invest 1993;92:2569-76.
66. Wojtowicz-Praga S, Verma UN, Wakefield L, Esteban JM, Hartmann D, Mazumder A. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother 1996; 19(3): 169-75.
67. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996; 93: 2909-14.
68. Wright JA, Turley E, Greenberg AH. Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy. Crit Rev Oncog 1993;4(5):473-92.
69. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity: implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993;92(6):2569-76.
70. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother 1992; 12(1); 1-12.
71. Rohr von A, Thatcher N. Clinical applications of interleukin-2. Prog Growth Factor Res 1992;4:229-46.
72. Ioannides CG, Whiteside TL. Short analytical review: T-cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol 1993:66(2): 91-106.
73. Tsukuda M, Mochimatsu I, Sakumoto M, Furukawa S. Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas. Biotherapy 1993; 6(20):155-61.
74. Schwartzentruber DJ, Stetler-Stevenson M, Rosenberg SA, Topalian SL. Tumor infiltrating lymphocytes derived from select B-cell lymphomas secrete GM-CSF and TNF alpha in response to autologous tumor stimulation. Blood 1993;82(4):1204-11.
75. Nouri AM, Bergbaum A, Lederer E, Crosby D, Shamsa A, Oliver RT. Paired tumor infiltrating lymphocyte (TIL) and tumor cell line from bladder cancer: a new approach to study tumor immunology in vitro. Eur J Cancer 1991; 27(5):608-12.
76. McAdam AJ, Felcher A, Woods ML, et al. Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes. J Immunother 1994;15(3):155-64.
77. Huber D, Philipp, Fontana A. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression. J Immunol 1992;148(1):277-84.
78. Koberda J, Grimm EA, Moser RP. Effect of anti-CD3/anti-CD28/ interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of Iymphokine-activated killer cell generation. J Cancer Res Clin Oncol 1993; 119(3): 131-6.
79. Maghazachi AA, al-Aoukaty A. Transforming growth factor-beta 1 is chemotactic for interleukin-2-activated natural killer cells. Nat Immun Cell Growth Regul 1993; 12(2): 57-65.
80. Ruscetti FW, Dubois CM, Jacobsen SE, Keller JR. Transforming growth factor beta and interleukin-1: a paradigm for opposing regulation of hemopoiesis. Baillieres Clin Haematol 1992; 5(3):703-21.
81. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res 1992;52(6):1386-92.
82. Qin L, Chavin KD, Ding Y, et al. Gene transfer for transplantation: prolongation of allograft survival with transforming growth factor-beta 1. Ann Surg 1994;220(4):508-18.
83. Delens N, Torreele E, Savelkool H, De Baetselier P, Bouwens L. Tumor-derived transforming growth factor-beta 1 and interleu-kin-6 are chemotactic for Iymphokine-activated killer cells. Int J Cancer 1994;57(5):696-700.
84. Geller RL, Smyth MJ, Strobl SL, et al. Generation of lymphokine activated killer activity in T cells: possible regulatory circuits. J Immunol 1991; 146 (10):3280-8.
85. Khew-Goodall Y, Gamble JR, Vadas MA. Regulation of adhesion and adhesion molecules in endothelium by transforming growth factor-beta. Curr Top Microbiol Immunol 1993; 184: 187-99.
86. Hsu S, Huang F, Friedman E. Platelet-derived growth factor-B increases colon cancer cell growth in vivo by a paracrine effect. J Cell Physiol 1995; 165(2):239-245.
87. Newman MJ. Transforming growth factor beta and the cell surface in tumor progression. Cancer Metastasis Rev 1993;12(3):239-54.
88. Chao CC, Hu S, Sheng WS, Tsang M, Peterson PK. Tumor necrosis factor-alpha mediates the release of bioactive transforming growth factor-beta in murine microglial cell cultures. Clin Immunol Immunopathol 1995;77(3):358-65.
89. +T and NK cells. J Exp Med 1994; 180(5): 1937-42.
90. Stavnezer J. Regulation of antibody production and class switching by TGF-beta. J Immunol 1995; 155(4): 1647-51.
91. Arteaga CL, Carty-Dugger T, Moses H, Hurd S, Pietenpol J. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athy-mic mice. Cell Growth Differ 1993;(4): 193-201.
92. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN. Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 1992;76(5):799-804.
93. Fischer JR, Darjes H, Lahm H, Schindel M, Drings P, Krammer PH. Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur J Cancer 1994;30A (14): 2125-9.
94. Damstrup L, Rygaard K, Spang-Thomsen M, Skovgaard Poulsen H. Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2 and TGF beta 3 in human small cell lung cancer cell lines. Br J Cancer 1993;67(5):1015-21.
95. Young MR, Wright MA, Coogan M, Young ME, Bagash J. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta. Cancer Immunol Immunother 1992;35(1):14-8.
96. Takanami I, Imamura T, Hashizume T, Kikuchi K, Yamamoto Y, Kodaira S. Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma. J Clin Pathol 1994; 47(12):1098-100.
97. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995;4(5):549-54.
98. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993; 105(6): 1846-56.
99. Maeurer MJ, Martin DM, Castelli C, et al. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1995;41(2):111-21.
100. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER. Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 1994;135(5):2240-7.
101. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 1993;24(1):4-9.
102. Miyamoto H, Kubota Y, Shuin T, Torigoe S, Dobashi Y, Hosaka M. Expression of transforming growth factor-beta 1 in human bladder cancer. Cancer 1995;75(10):2565-70.
103. Williams AO, Ward JM, Li JF, Jackson MA, Flanders KC. Immunohistochemical localization of transforming growth factor beta 1 in Kaposi’s sarcoma. Hum Pathol 1995;26(5):469-73.
104. Szymkowiak CH, Mons I, Gross WL, Kekow J. Determination of transforming growth factor beta 2 in human blood samples by ELISA. J Immunol Methods 1995;184(2):263-71.
105. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995;222(2):155-62.
106. Kopp A, Jonat W, Schmahl M, Knabbe C. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 1995;55(2):4512-5.
107. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med 1995;1(4):282.
108. Eder IE, Stenzl A, Cronauer MV, Bartsch G, Klocker H. Transforming growth factor beta 1 and beta 2 and basic fibroblast growth factor in serum and urine from patients with bladder cancer. Proc Am Assoc Cancer Res 1995;(36):245.
109. Shirai Y, Kawata S, Ito N, et al. Elevated levels of plasma transforming growth factor p in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992;83:676-9.
110. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995; 92: 2572-6.
111. Wakefield LM, Letterio JJ, Chen T, et al. Transforming growth factor beta-1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995; 1: 129-36.
112. Assoian RK, Sporn MB. Type fi transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol 1986;102:1217-23.
113. Puolakkainen P, Twardzik D, Ranchalis J, Moroni M, Mandeli J, Paciucci PA. Increase of plasma transforming growth factor beta (TGF beta) during immunotherapy with IL-2. Cancer Invest 1995; 13(6):583-9.
114. Ruscetti F, Varesio L, Ochoa A, Ortaldo J. Pleiotropic effects of transforming growth factor-beta on cells of the immune system. Ann N Y Acad Sci 1993;685:488-500.
115. Hoefer M, Anderer FA. Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Cancer Im-munol Immunother 1995;41(5):302-8.
116. Gridley DS, Sura SS, Uhm JR, Lin CH, Kettering JD. Effects of anti-transforming growth factor-beta antibody and interleukin-2 in tumor-bearing mice. Cancer Biother 1993;8(2):159-70.
117. Mao XW, Kettering JD, Gridley DS. Immunotherapy with low dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model. Cancer Biother 1994;9(4):317-27.
118. Holland G, Zlotnik A. Interleukin-10 and cancer. Cancer Invest 1993; 11 (6):751-8.
119. Stuart AD, Stewart JP, Arrand JR, Mackett M. The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes. Oncogene 1995;11(9):1711-9.
120. Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD, Lotze MT. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 1995;182(2):477-86.
121. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10: a role for IL-10 in induction of tolerance. J Immunol 1993; 151 (5):2390-8.
122. Baiocchi RA, Ross ME, Tan JC, et al. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood 1995;85(4):1063-74.
123. Carson WE, Lindemann MJ, Baiocchi R, et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995;85(12):3577-85.
124. Gastl GA, Abrams JS, Nanus DM, et al. Interleukin-10 produc-tion by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993;55(1):96-101.
125. Huettner C, Paulus W, Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 1995; 146(2):317-22.
126. Huang M, Wang J, Lee P, et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995;55(17):3847-53.
127. Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994;56(5):755-60.
128. Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 1995;41(3):151-6.
129. Nakagomi H, Pisa P, Pisa EK, et al. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 1995;63(3):366-71.
130. Kim J, Modlin RL, Moy RL, et al. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J Immunol 1995; 155(4): 2240-7.
131. Masood R, Zhang Y, Bond MW, et al. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome related B-cell lymphoma. Blood 1995;85 (12):3423-30.
132. Clerici M, Wynn TA, Berzofsky JA, et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994; 93(2):768-75.
133. Benjamin D, Park CD, Sharma V. Human B cell interleukin 10. Leuk Lymphoma 1994; 12(3-4):205-10.
134. Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1995; 85(9):2516-20.
135. 2. J Immunol 1995;155(9):4437-44.
136. 2 production and metabo-lism in human breast cancer cells and breast fibroblasts: regulation by inflammatory mediators. Br J Cancer 1995;72(6):1412-9.
137. 2 production in fresh tissues of head and neck cancer patients. Head Neck 1995; 17(2): 108-13.
138. Klapan I, Katie V, Culo F, Cuk V. Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer. J Cancer Res Clin Oncol 1992; 118(4):308-13.
139. 2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. Biochemistry 1995;34 (16): 5604-9.
140. 2 suppresses in vitro cellular immune responses. Am J Physiol 1995;269(1 Pt 2):R92-7.
141. 2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995; 181 (2):775-9.
142. 2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 1993;72(2):491-501.
143. Marnett LJ. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prev Med 1995;24(2):103-6.
144. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995;55(7):1464-72.
145. Chao TY, Ting CS, Yeh MY, Chang JY, Wang CC, Chu TM. Effects of indomethacin on lymphokine-activated killer cell activities in cancer patients. Tumor Biol 1995;16(4):230.
146. Boolbol SK, Dannenberg AJ, Chadbum A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56(11):2556-60.